Update on current practice in laboratory medicine in respect of natriuretic peptide testing for heart failure diagnosis and management in Europe. The CARdiac MArker guideline Uptake in Europe (CARMAGUE) study.

Hammerer-Lercher, Angelika;Gruson, Damien;Stankovic, Sanja;Collinson, Paul;EFLM Task Group Cardiac Markers;et.al.
(2020) Clinica Chimica Acta — Vol. 511, p. 59-66 (2020)

Files

2020_Hammerer-Lercher_Clin_Chim_Acta_A.pdf
  • Open Access
  • Adobe PDF
  • 451.97 KB
Download
2020_Hammerer-Lercher_Clin_Chim_Acta.pdf
  • Restricted Access
  • Adobe PDF
  • 813.67 KB
Request a copy

Details

Authors
  • Hammerer-Lercher, Angelika
    Author
  • Gruson, DamienUCLouvain
    Author
  • Stankovic, Sanja
    Author
  • Collinson, Paul
    Author
  • EFLM Task Group Cardiac Markers
    Collaborator
Show more
Abstract
BACKGROUND: The European Federation of Clinical Chemistry and Laboratory Medicine (EFLM) initiated the CArdiac MARker Guidelines Uptake in Europe (CAMARGUE) Study to survey if current biomarker testing for heart failure (HF) in Europe is in accordance with up-dated guidelines. METHODS: A web-based questionnaire was distributed to clinical laboratories via European biochemical societies in 2019. Questions covered the type of natriuretic peptide (NP) assays performed, decision limits for HF, and opinion concerning requirement of different thresholds in patients with renal failure or obesity. RESULTS: There were 347 participating laboratories mostly from European countries with 266 offering NP testing. NP testing was increased from 67% to 77% between 2013 and 2019. NT-proBNP remained the preferred biomarker. Recommended decision limits were implemented for BNP (85%) and better focused for NT-proBNP (40%) than in the previous survey. The survey revealed that laboratorians are willing to support the translation of adjusted cut-off values for age, gender and for patients with conditions like renal insufficiency. CONCLUSION: Guidelines stimulate clinical laboratories to offer NP testing with high value for the diagnosis and management of HF, and to present adjusted medical decision limits. Future guidelines should encourage the use of personalized cut-offs for some confounding factors.
Affiliations

Citations

  • APA
  • Chicago
  • FWB

Hammerer-Lercher, A., Gruson, D., Stankovic, S., Collinson, P., Suvisaari, J., Pulkki, K., Duff, C. J., Baum, H., Stavljenic-Rukavina, A., Aakre, K. M., Langlois, M. R., & Laitinen, P. (2020). Update on current practice in laboratory medicine in respect of natriuretic peptide testing for heart failure diagnosis and management in Europe. The CARdiac MArker guideline Uptake in Europe (CARMAGUE) study. Clinica Chimica Acta, 511, 59-66. https://doi.org/10.1016/j.cca.2020.09.030 (Original work published 2020)